Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report

doi:10.12998/wjcc.v10.i18.6184

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3492)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

220

WORD

133

HTML

1808

Figures (1-3)

207

Tables (1-1)

223

Sum=2591

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

281

Download

620

Sum=901

Jun 26, 2022 (publication date) through Jul 18, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Jun 26, 2022; 10(18): 6184-6191
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6184

Table 1 Summary of neoadjuvant immunotherapies for gastric carcinoma

Regimen	Neoplasm	Number of participants	pCR rate	MPR	Ref.
Camrelizumab plus FOLFOX	Locally advanced gastric carcinoma and adenocarcinoma of the esophagogastric junction	26	2 (9%)	8 (36%)	[17]
Sintilimab plus FLOT	Gastric and adenocarcinoma of the esophagogastric junction	17	3/17 (17.6%)	10/17 (58.8%)	[18]
Sintilimab plus CapeOX	Locally advanced resectable gastric/adenocarcinoma of the esophagogastric junction	26	6/26 (23.1%)	14/26 (53.8%)	[19]

MPR: Mannose 6-phosphate receptors; pCR: Pathologic complete response.

Citation: Liu R, Wang X, Ji Z, Deng T, Li HL, Zhang YH, Yang YC, Ge SH, Zhang L, Bai M, Ning T, Ba Y. Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. World J Clin Cases 2022; 10(18): 6184-6191
URL: https://www.wjgnet.com/2307-8960/full/v10/i18/6184.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i18.6184